Peer-reviewed veterinary case report
Stereotactic radiation for nasal lymphoma in cats - what to expect
By Reczynska, Alicja I et al.·Published in Journal of veterinary internal medicine·2022·Department of Environment and Radiological Health Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of stereotactic body radiation for treatment of nasal and nasopharyngeal lymphoma in 32 cats.
- Species:
- cat
Plain-English summary
A group of 32 cats with nasal lymphoma received stereotactic body radiation therapy (SBRT) to treat their condition. The treatment was generally well-tolerated, and the cats had a median survival time of about a year, with many experiencing no immediate side effects. Some cats did develop late effects like dry eyes and hair loss, but overall, SBRT proved to be an effective option for managing this type of cancer in cats. This treatment could be a good choice for cats with localized nasal lymphoma, especially those in earlier stages of the disease.
People also search for: cat nasal lymphoma treatment · stereotactic radiation therapy for cats · cat cancer survival rates · side effects of radiation in cats
Abstract
BACKGROUND: The safety and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of localized nasal lymphoma in cats has not been described. HYPOTHESIS: Stereotactic body radiation therapy with or without adjuvant chemotherapy is an effective and well-tolerated treatment for localized nasal lymphoma in cats. ANIMALS: Thirty-two client owned cats referred to Colorado State University for the treatment of nasal lymphoma. METHODS: Retrospective study of cats treated with SBRT between 2010 and 2020 at Colorado State University. Diagnosis of nasal lymphoma was obtained via cytology or histopathology. Signalment, radiation protocol, concurrent treatments, adverse effects, and survival were recorded. RESULTS: Progression free survival was 225 days (95% CI 98-514) and median survival time (MST) was 365 days (95% CI 123-531). No significant difference in survival was identified between cats that received 1 versus greater than 1 fraction (MST 427 vs. 123 days, P = 0.88). Negative prognostic factors included cribriform lysis (MST 121 vs. 876 days, P = 0.0009) and intracalvarial involvement (MST 100 vs. 438 days, P = 0.0007). Disease progression was noted in 38% (12/32), locally in 22% (7/32), and systemically in 16% (5/32). No cats developed acute adverse effects. Ten cats developed late adverse effects: keratitis/keratitis sicca (n = 2), alopecia (n = 4), and leukotrichia (n = 4). Twenty-four cats (75%) had signs consistent with chronic rhinitis. CONCLUSIONS: SBRT is effective and well tolerated for treating localized nasal lymphoma in cats. Outcomes for cats with lower stage disease (canine modified Adam's stage 3 and lower) are comparable to historic data of cats treated with fractionated radiation therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35188694/